AorTech to buy Becton Dickinson's critical care unit for $52 million
This article was originally published in Clinica
UK company AorTech has entered into a non-binding letter of intent with Becton Dickinson to buy its critical care business for around $52 million. AorTech will pay half of the amount upfront, with funding coming mainly from debt finance and cash resources. The remainder, which will be subject to sales performance adjustments, will be paid over 30 months. Final negotiations between the two companies are ongoing.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.